Briefing
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies
In a real-world Signatera series of 101 patients with stage I uterine malignancies, postoperative ctDNA positivity was associated with inferior recurrence-free survival (HR 6.2 at the first time point and HR 15.5 longitudinally) and remained prognostic after adjustment for clinicopathologic risk factors.
- Design: Evidence level 3
- Assay: Not named in the abstract